Immunome to Acquire Antibody-Related Assets and Materials from Atreca
26 Dicembre 2023 - 2:30PM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced that it entered into a definitive asset
purchase agreement with Atreca, Inc. (Nasdaq: BCEL) to acquire a
collection of antibody-related assets and materials.
“We believe that novel and underexplored targets will drive the
next generation of transformative ADCs. These antibody-related
assets will expand our toolbox, complementing our existing programs
as we advance our mission of developing innovative treatments for
cancer patients,” stated Clay B. Siegall, Ph.D., Chairman and Chief
Executive Officer of Immunome.
Under the terms of the asset purchase agreement, Immunome would
pay Atreca a $5.5 million upfront payment and up to $7.0 million in
clinical development milestones. Completion of the transaction is
subject to customary conditions including Atreca obtaining a
required stockholder vote.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including immunotherapies, targeted effectors, radioligand
therapies and ADCs. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We use words such as
“believes,” “plans,” “expects,” “will,” “assumes,” “anticipates,”
and similar expressions to identify these forward-looking
statements that are intended to be covered by the safe-harbor
provisions of the PSLRA. These forward looking statements include,
but are not limited to, statements regarding Immunome’s expectation
that the purchase of assets from Atreca will close and, if closed,
will complement Immunome’s development pipeline; and other
statements regarding management’s intentions, plans, beliefs,
expectations or forecasts for the future. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. Such forward-looking statements
are based on our expectations and involve risks and uncertainties;
consequently, actual results may differ materially from those
expressed or implied in the statements due to a number of factors,
including, but not limited to, the risk that the transaction with
Atreca will not be completed, Immunome’s ability to grow and
successfully execute on its business plan, including advancing its
current pipeline and any additionally acquired assets into the
clinic and expanding its pipeline through its technology platforms,
proprietary toolbox and the Atreca transaction and other strategic
transactions, if any; the ability of Immunome to identify, conduct
and complete IND-enabling studies; changes in the applicable laws
or regulations; the possibility that Immunome may be adversely
affected by other economic, business, and/or competitive factors;
the risk that regulatory approvals for Immunome’s programs and
product candidates are not obtained, are delayed or are subject to
unanticipated conditions that could adversely affect it or the
expected benefits of the Atreca transaction; Immunome’s ability to
manage clinical trials or studies; the risk that pre-clinical data
may not be predictive of clinical data; the complexity of numerous
regulatory and legal requirements that Immunome needs to comply
with to operate its business; the reliance on Immunome’s
management; the prior experience and successes of the Immunome’s
management team are not indicative of any future success;
uncertainties related to Immunome’s capital requirements and
Immunome’s expected cash runway; the failure to obtain, adequately
protect, maintain or enforce Immunome’s intellectual property
rights; and other risks and uncertainties indicated from time to
time described in Immunome’s Annual Report on Form 10-K for the
year ended December 31, 2022 filed with Securities and Exchange
Commission (“SEC”) on March 16, 2023, Immunome’s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2023 filed with
the SEC on November 9, 2023, and in Immunome’s other filings with
the SEC. Immunome cautions that the foregoing list of factors is
not exclusive and not to place undue reliance upon any
forward-looking statements which speak only as of the date made.
Moreover, Immunome operates in a very competitive and rapidly
changing environment. New risks emerge from time to time. Except as
required by law, Immunome does not undertake any obligation to
update publicly any forward-looking statements for any reason after
the date of this press release to conform these statements to
actual results or to changes in their expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231226547244/en/
Investor
Corleen Roche Chief Financial Officer investors@immunome.com
Grafico Azioni Immunome (NASDAQ:IMNM)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Immunome (NASDAQ:IMNM)
Storico
Da Lug 2023 a Lug 2024